**Objectives**

- To evaluate the response rate of eftilagimod alpha given in combination with pembrolizumab in patients with advanced/metastatic NSCLC (PD-X naïve, 1st line and PD-X refractory, 2nd line) and recurrent HNSCC
- To further evaluate the safety, tolerability and antitumor activity of eftilagimod alpha when combined with pembrolizumab
- To assess the pharmacokinetic and immunogenic properties of eftilagimod alpha

**Treatment**

The treatment consists of an immuno-immunotherapy combo phase followed by a monotherapy phase:

- **Combo phase:** 8 cycles of 3 weeks with pembrolizumab (200 mg iv.) q3w and eftilagimod alpha (30 mg sc.) q2w; followed by **10 cycles** of 3 weeks with pembrolizumab (200 mg iv.) and eftilagimod alpha (30 mg sc.) both given q3w
- **Monotherapy phase:** 17 cycles of 3 weeks with pembrolizumab (200 mg iv.) q3w

**Other key inclusion and exclusion criteria**

**Inclusion:**
- Submission of formalin-fixed diagnostic tumor tissue
- ECOG performance status 0-1
- Expected survival longer than three months

**Exclusion:**
- Part A 1st line, PD-X naïve NSCLC amenable for curative standard of care, received systemic therapy for stage IV or amenable to EGFR/ALK based therapy
- Part B 2nd line, PD-X refractory NSCLC with symptomatic ascites or pleural effusion or >1 line of chemotherapy for metastatic disease
- Part C 2nd line PD-X naïve HNSCC amenable to curative treatment or >1 systemic regimen for recurrent and/or metastatic disease
- Prior anti-PD-X therapy or other immunotherapy targeting T-cell co-stimulation or checkpoint pathways (Part A and B only)
- Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137) and was discontinued from that treatment due to a Grade 3 or higher irAE (Part B only)
- Systemic anti-cancer therapy, major surgery or any other investigational agent within 4 weeks prior to first dose of study treatment
- Known cerebral or leptomeningeal metastases
- Any condition requiring continuous systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 7 days prior to first dose of study treatment

**Study population**

- **Part A** (1st line, PD-X naïve NSCLC): histologically- or cytologically-confirmed diagnosis of non-small cell lung carcinoma stage IIIB not amenable to curative treatment or stage IV not amenable to EGFR/ALK based therapy, treatment naïve for systemic therapy given for advanced/metastatic disease (previous palliative radiotherapy for advanced/metastatic disease acceptable)
- **Part B** (2nd line, PD-X refractory NSCLC): histologically- or cytologically-confirmed diagnosis of NSCLC after failure of first-line treatment (for metastatic disease) with at least 2 cycles of any PD-1/PD-L1 containing based therapy alone, or in combination with any other immunotherapeutic or chemotherapy
- **Part C** (2nd line PD-X naïve HNSCC): histologically- or cytologically-confirmed recurrent disease not amenable to curative treatment with local or systemic therapy, or metastatic (disseminated) HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx that is considered incurable by local therapies after failure of prior platinum-based therapy

**Trial design**

A multicenter, open-label, Phase II clinical trial applying Simon’s 2-stage design

During the first stage the number of N1 patients will be recruited. In case there are more responses than threshold (r1) observed in patients recruited in Stage 1, additional patients (N2) will be recruited in Stage 2

**Involving countries**

- The Tacti-002 trial was submitted and approved in 4 countries and 13 sites:  
  - Australia  
  - United Kingdom  
  - Spain  
  - United States of America

**Study duration**

- Status: approvals from all competent authorities and ECs/IRBs received
- First patient in: 05 March 2019
- Status as of 21 May 2019: 21/58 subjects enrolled in Stage 1
- Estimated primary completion date (Stage 1): H2/2019

**Statistical analysis**

- N = 58 (Stage 1) + 51 (Stage 2)
- All efficacy analyses will be based on Investigator’s assessment acc. to iRECIST